Login to Your Account



Attaboy, Yervoy!

Better-than-Expected Label for BMS' Ipilimumab in Melanoma

By Jennifer Boggs


Monday, March 28, 2011
Bristol-Myers Squibb Co. is planning a quick rollout of ipilimumab following its Friday approval as the first drug to demonstrate improvement in overall survival in metastatic melanoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription